MX2021011250A - Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico. - Google Patents
Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico.Info
- Publication number
- MX2021011250A MX2021011250A MX2021011250A MX2021011250A MX2021011250A MX 2021011250 A MX2021011250 A MX 2021011250A MX 2021011250 A MX2021011250 A MX 2021011250A MX 2021011250 A MX2021011250 A MX 2021011250A MX 2021011250 A MX2021011250 A MX 2021011250A
- Authority
- MX
- Mexico
- Prior art keywords
- lymphoma
- benzylthio
- bis
- compositions
- octanoic acid
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- GXDQJPLRORWRMG-UHFFFAOYSA-N 6-benzyl-9-phenylnonanethioic s-acid Chemical compound C=1C=CC=CC=1CC(CCCCC(=O)S)CCCC1=CC=CC=C1 GXDQJPLRORWRMG-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229940121548 devimistat Drugs 0.000 abstract 2
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 abstract 1
- ZYRLHJIMTROTBO-UHFFFAOYSA-N 6,8-bis(benzylsulfanyl)octanoic acid Chemical compound C=1C=CC=CC=1CSC(CCCCC(=O)O)CCSCC1=CC=CC=C1 ZYRLHJIMTROTBO-UHFFFAOYSA-N 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 229960001215 bendamustine hydrochloride Drugs 0.000 abstract 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 abstract 1
- ZYRLHJIMTROTBO-OAQYLSRUSA-N devimistat Chemical compound C([C@@H](CCCCC(=O)O)SCC=1C=CC=CC=1)CSCC1=CC=CC=C1 ZYRLHJIMTROTBO-OAQYLSRUSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820767P | 2019-03-19 | 2019-03-19 | |
| PCT/US2020/023537 WO2020191144A1 (en) | 2019-03-19 | 2020-03-19 | Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011250A true MX2021011250A (es) | 2022-02-11 |
Family
ID=72519349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011250A MX2021011250A (es) | 2019-03-19 | 2020-03-19 | Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220151994A1 (https=) |
| EP (1) | EP3941453A4 (https=) |
| JP (1) | JP2022525779A (https=) |
| KR (1) | KR20220018959A (https=) |
| CN (1) | CN114040758A (https=) |
| AU (1) | AU2020240091A1 (https=) |
| BR (1) | BR112021018138A2 (https=) |
| CA (1) | CA3133101A1 (https=) |
| MX (1) | MX2021011250A (https=) |
| TW (1) | TW202102211A (https=) |
| WO (1) | WO2020191144A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3121645A1 (en) * | 2018-12-20 | 2020-06-25 | Rafael Pharmaceuticals, Inc. | Oral therapy using 6,8-bis-benzylthio-octanoic acid |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263653B2 (en) * | 2007-04-18 | 2012-09-11 | Cornerstone Pharmaceuticals, Inc. | Pharmaceutical formulations containing lipoic acid derivatives |
-
2020
- 2020-03-19 MX MX2021011250A patent/MX2021011250A/es unknown
- 2020-03-19 CN CN202080022886.3A patent/CN114040758A/zh active Pending
- 2020-03-19 CA CA3133101A patent/CA3133101A1/en active Pending
- 2020-03-19 EP EP20774107.5A patent/EP3941453A4/en not_active Withdrawn
- 2020-03-19 KR KR1020217033115A patent/KR20220018959A/ko active Pending
- 2020-03-19 TW TW109109207A patent/TW202102211A/zh unknown
- 2020-03-19 WO PCT/US2020/023537 patent/WO2020191144A1/en not_active Ceased
- 2020-03-19 US US17/440,229 patent/US20220151994A1/en not_active Abandoned
- 2020-03-19 BR BR112021018138A patent/BR112021018138A2/pt unknown
- 2020-03-19 AU AU2020240091A patent/AU2020240091A1/en not_active Abandoned
- 2020-03-19 JP JP2021556419A patent/JP2022525779A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220018959A (ko) | 2022-02-15 |
| WO2020191144A1 (en) | 2020-09-24 |
| AU2020240091A1 (en) | 2021-09-30 |
| EP3941453A4 (en) | 2022-12-28 |
| CA3133101A1 (en) | 2020-09-24 |
| JP2022525779A (ja) | 2022-05-19 |
| BR112021018138A2 (pt) | 2021-11-16 |
| TW202102211A (zh) | 2021-01-16 |
| US20220151994A1 (en) | 2022-05-19 |
| EP3941453A1 (en) | 2022-01-26 |
| CN114040758A (zh) | 2022-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| IL251185A0 (en) | mek inhibitors and methods of using them | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| MXPA05012466A (es) | Derivados de quinolina como inhibidores de fosfodiesterasa. | |
| SG148202A1 (en) | Quinazolinone compounds as anticancer agents | |
| MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
| TNSN06228A1 (en) | Compounds and methods of use | |
| WO2005013892A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| MXPA05007462A (es) | Derivados de pirrolopiridazina. | |
| TW200606162A (en) | Pyrazolopyridine derivatives | |
| WO2006113498A3 (en) | 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| MX2021011250A (es) | Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. |